Gilead says Trodelvy-Keytruda combo effective for aggressive breast cancer type

(Reuters) - Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's immunotherapy Keytruda significantly slowed disease progression in patients with an aggressive type of breast cancer. The Phase 3 trial compared the Trodelvy-Keytruda combo to a standard initial treatment of chemotherapy and Keytruda in 443 previously untreated patients